By Colin Kellaher
Mineralys Therapeutics shares surged to a new 52-week high Monday after the clinical-stage biopharmaceutical company reported positive study results for its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.
Shares of the Radnor, Pa., company were recently changing hands at $15.07, up 43%, after touching a 52-week high of $15.64 early in the session.
Mineralys said a pair of pivotal studies of lorundrostat achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints, and that the results demonstrate the opportunity for the drug in third-line or later treatment.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 10, 2025 09:57 ET (13:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.